Pursuant to Regulation 29 & 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mankind Pharma has informed that a meeting of Board of Directors of the Company will be held on Tuesday, November 5, 2024, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2024. Further, in continuation of earlier letter dated September 25, 2024 under subject ‘Closure of Trading Window’ under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till November 7, 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com.
The above information is a part of company’s filings submitted to BSE.
